Ignite Creation Date:
2025-12-24 @ 2:17 PM
Ignite Modification Date:
2026-05-31 @ 2:51 PM
Study NCT ID:
NCT03625895
Status:
COMPLETED
Last Update Posted:
2023-02-27
First Post:
2018-08-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Agrylin Drug Use-Result Survey
Sponsor:
Takeda
Organization:
Study Overview
Official Title:
Agrylin Capsules 0.5 mg Drug Use-Result Survey
Status:
COMPLETED
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this survey is to collect data to evaluate the safety and efficacy of anagrelide hydrochloride in the post-marketing phase in participants diagnosed with Essential Thrombocythemia (ET).
Detailed Description:
Anagrelide hydrochloride Drug Use-Result Survey
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: